Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
you're probably right. I just thought some of of the info was interesting such as debt and share count. Not necessarily market cap.
Nice job.
It would be nice to have this added the IBOX .
LMAO Champ. Thanks for the tip.
Pls delete post 1154, I found my answer and dont want to start unwarranted rumors...
TIA
$23.50 drops us 34%.
Occasional news would tighten that spread and keep it tight.
If we see the price drop for year end tax losses I might think about picking up more
Hopefully news will start Jan 2018
I thought i read somewhere that this may r/s x 8. Can you or any others confirm or clarify this?
TIA
Looks great. Thanks for the effort
Thanks for the charting and more importantly the corresponding analysis.
This sure helps while trying to learn the charts..
Also imo the Alternative Agroscience ETF could be in play as well.
I hope your close with this number....
Im counting on that. You were spot on with your previous prediction .
unless they play the steelers.
the loss today probably knocked us out of the playoffs. You and Farmer now have another Vikings fan ....
Thanks and same to you. Props to 1990....
December will pass with a snap of a finger ,2018 will be here before you know it.
Good times ahead Globally for OWCP .
Ill really be thankful, if my Lions can beat your Vikings today.
1990 Tuesday, 03/14/17 07:07:52 PM
Re: None
Post # of 121098
Ok so I want to start off with a few things before I get into the interview. I would like to start off by commending Ziv. He was willing to meet with me at 8am (even though they start work significantly later to mirror American hours) and he allotted essentially an infinite amount of time for me. I want to follow up with an apology to you guys. I had to catch a flight and this was very last minute so I only had about half an hour with him. I didn't get to get as deep into it as I would like or get to ask all the questions submitted. That being said I will detail the brief interview below. There will be some places where I insert my opinion and I will make those points clear.
First and foremost the office definitely exists guys haha. It's a standard office with a beautiful lobby in a mini office park. The outside looks average but inside it looks modern. I took a few pictures and am on my phone now. Maybe I can post them from my computer later? I also passed by tel hashomer hospital. I have asked many people there about it and it's reputation is outstanding.
Now on to the interview
Q: what other uses are being tested for the cream? I believe I heard something about basal cell carcinoma
A: I can't get into those details but I can tell you basal cell carcinoma is not something we are testing now. It is definitely on our radar for the near future
Q: does the cream have any side effects? What makes it different from other products?
A: no there are no side effects which is a benefit of this cream unlike other medications. Also our product is natural and does not have chemicals in it like other treatments. Furthermore I believe our product will be the only psoriasis cream clinically tested on the market. If you can find another cream that was let me know (this is Ziv btw)
Q: what country do you plan to market to first?
A: US but we are also excited to take advantage of the European market. It's huge and often gets overlooked.
Q: so you want to enter the US market. This is through Medmar correct? Is this the same one in Illinois?
A: yes we will distribute through Medmar. No it's not the same company in Illinois.
Q: consulting contracts. When do you expect to generate revenue from them
A: sometime this year
Q: any myeloma updates?
A: not that I can say
Q: well are you more advanced then the previous article about killing 100% in 60% of myeloma cells in tested animals?
A: yes we are more advanced than that. I can't comment on specifics unfortunately. I don't want to tip off competition.
Q: how many patents do you have. Are they all provisional? Are they all protected by USPTO?
A: 8 provisional and they are all protected by USPTO. We filled the provisional with the intention of working our way to a real patent. It's a process. We also filled a PCT patent on five of them which extends our ownership of idea and time period for 18 months as we flush out these concepts further. But yes these are currently protected.
Q: is the condom one of those
A: of course it could be a fun way to take/give medication
Q: what other diseases are currently in the pipeline?
A: I cannot mention anything that wasn't published but there are others
Q: who do you see as your biggest competitor?
A: no competition at the moment. There are so many possibilities for cannabis and medical application that there isn't any reason for people to step on each other's toes. The more people who embrace cannabis the more beneficial it is for the industry.
Q: will you touch the raw plant or just oils
A: just oils for now
Q: are the rumors about Teva trying to buy you out true?
A: they called us and wanted to sign an NDA to have access to our information. There was no reason for us to give them access to our intellectual property/information so we denied their request.
Q: why did you go public?
A: three years ago cannabis was not taken seriously. When I told my mother what I was doing she thought I was a drug dealer and wanted nothing to do with it. Others had a similar reaction At the time buying the ticker was the only way to raise funds. If I could have raised the money at the time I would have preferred to be private. (MY OPINION: now cannabis is more widely accepted I think their recent partnerships and agreements point to this. Their non dilutive financing points to their current goals not to just keep issuing shares. I also think this rarity is why we have found such a gem and ground floor opportunity. Had cannabis been widelt accepted in 2014 I don't think theyd be public right now )
Me: well I'm glad you went public haha
He then let me see the cream. While I don't have psoriasis I can say the cream didn't have any noticable negative effects on my skin. Cream is kind of thick and you can smell the weed haha but the smell subsidies after rubbing it on.
MY OPINION: while he didn't say it, from my own interpretations of body language and context clues, I believe efficacy is a given. It almost seemed as if it was assumed that it was coming to market throughout our convo Once again this is my opinion not fact.
Also MY OPINION from talking to him he is aware of the fluctuations in the stock price but doesn't seem concerned. I get the impression he believes long term everything will work itself out.
Overall he was very nice and willing to answer all my questions. I know there are quite a few topics that might have benefitted from a deeper dive but do to my own time restrictions I couldn't get to those. I hope at least one of these answers helps y'all in your DD
IDK. the seller nearly doubles his cash or position.IF this happened
Selling into the bid on the open market wouldn't affect the companies share structure.
I'm just thinking out loud. Another thought is if we are debt free,have pending orders, why not get a loan?
Need fins.
let's hope so
I believe there was some warrants or private placement sold.
I also believe that1-1.5 mil dump was by a long who acquired cheaper via PP of some sots.
I would be happily surprised if the outstanding shares were 175 million; however, I don’t think were that fortunate. I guess we’d know if fins were published...
IMO
The name of the original ETF was Agrosphere..
https://www.sec.gov/Archives/edgar/data/1467831/000114420417009539/v459698_485apos.htm
BTW I never busted your chops or Loseitall's on the MSU / PSU game
I figured autocorrect
Patent, not patient.....
I missed on buying yesterday; but, I added on the dip.
Slowly Im building my long position, without flipping for shares....
IT WAS A COMPLIMENT!
Nice call on your timeline for news!
Good read regarding cannabis compared to alcohol.
https://amp.businessinsider.com/alcohol-marijuana-which-worse-health-2017-11?ref=yfp
TD Ameritrade is free
Agreed, would be nice to know the share structure
Thanks for the response.
My initial thought was to ask you to pm me your email address so I discuss with you something offline; however, I did nt think you'd be receptive to it...
Ive felt for a while now that you have had communications with more JW vs JN mainly due to your Geographic proximity to each other.
I just hope you understand the decades of Frustration some of us have been thru and reasoning why we're starting to get agitated. Not one response, not one shareholder update....
Ive been in touch with a half dozen posters off-site and spoke with 3-4 on the phone. maybe a few you communicate with as well.
You have a pay membership and can review my first posting history on this board to confirm my posting consistency, if you choose. Start with the first 1 if you do...
Have you every been in contact with John Nordstrom or John Williams?
Ive been a shareholder approximately 20 years.
Never had one bit of correspondence replied to...
Do you think Ive been patient?
Dark Lady care to tell us how patient you've been? Be honest now....
Once you sounded like a broken record because nobody would respond to you.
Now that you are privy to information that the rest of us dont have, your tune has change.
Ed When did you buy your first lump of shares?
When did you buy your first shares?
Weekend at Bernies lol
Can one of the mods add this to the I-Box?
Morning Dawg!
Everyday's a good day, some are just better than others....
$LPPI
It's not MJ LPP1
LOL,
I hearing the same in another ticker I'm in. It's killing me; however, If true will be worth the wait..
I’m content with their credentials. Their accomplishments speak for themselves.
No need to compare....
OUR LEADERSHIP TEAM
OWC Pharmaceutical Research Corp.
Dr. Stanley Hirsch – Chairman
Dr. Hirsch joined OWCP as Chairman of our Board of Directors in July 2017. He has had extensive scientific, executive and board level experience for more than 25 years in private and publicly listed companies in biopharmaceutical and agricultural biotech industries, inter alia, including direct experience in raising capital and leading M&A activity. This experience, together with his multi-cultural management skills, having managed companies in Israel, Brazil, UK, China and the United States, is directly relevant to OWCP’s scientific and business development efforts.
Dr. Hirsch has served as Group CEO of FuturaGene Limited and its predecessor company, FuturaGene Plc., since 2007. He has also served as Chairman of the Board of Directors of Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), since 2016. and
Dr. Hirsch holds a D. Phil (1982) in Cell Biology and Immunology from Oxford University, UK. His educational experience also includes a B.Sc. degree with Honors in Medical Biochemistry from the University of Cape Town, South Africa (1979) among other academic honors and awards from Oxford University and University of Cape Town.
Mr. Mordechai Bignitz – Chief Executive Officer (CEO)
motiMr. Mordechai Bignitz is a seasoned financial manager, with over 30 years’ experience in operational and investment management, specializing in all aspects of the planning and execution of deals in private and public companies. Mr. Bignitz served as CEO of Geffen Green Energy Ltd. and as a director of Leader Capital Markets Ltd. (TASE: LDRC) and Leader Holdings & Investments Ltd. (TASE: LDER). He has extensive experience in the management of investments and financial systems, accounting and taxation and has been involved in economic and financial consulting to companies in the field of technology.
Mr. Bignitz is a CPA, with a BA in Accounting and Economics from Tel-Aviv University and completed the Executive Program in Management and Strategy in Retail at Babson College in Boston.
Mr. Yossi Dagan, CPA (IL) – Chief Financial Officer (CFO)
Mr. Yossi Dagan has extensive experience with Nasdaq-listed companies in various industries and provides financial, capital markets, accounting and regulatory expertiseto OWCP.
Mr. Dagan has served as CFO of Top Image Systems Ltd. (NASDAQ: TISO), since 2015. TISA is a global company with operations in the USA, Israel, Germany, UK, Singapore, Japan and Brazil. Mr. Dagan previously served as VP of Finance at Kenshoo – an Israeli based global SaaS company employing 600 employees, as Corporate Controller at Imperva Inc. – a leading provider of cyber security solutions that protect business-critical data and applications, and as a manager at PriceWaterhouseCoopers.
Mr. Dagan is a CPA with a BA in Accounting and Business from The College of Management, Rishon Le’Zion, Israel.
Mr. Jeffrey Friedland – Advisory Board Member
Mr. Jeffrey Friedland is an emerging markets pioneer. Friedland Global Capital Pte. Ltd. was one of the first American investment banks to establish a presence in China. Mr. Friedland , has been at the forefront of the global cannabis industry as an investor as well as business owner.
In his book “Marijuana: The World’s Most Misunderstood Plant”, Mr. Friedland examines the world of medical marijuana, discussing the plant’s history, what we know about the plant and its undeveloped potential. Mr. Friedland has been a frequent speaker at conferences and events dealing with individual and institutional investors on investments, emerging markets, and the global cannabis industry.
Ms. Miriam (Miri) Sani, M.Sc Eng. – Advisory Board Member
Ms. Miri Sani holds an M.Sc. in Chemistry from the Technion – Israel Institute of Technology, Haifa, Israel.
Ms. Sani is the CEO and owner of “Shefa Amirim” Ltd, which provides regulatory affairs and clinical consultation services for early-stage start-ups in various medical fields. During the past five years, Ms. Sani has shepherded various projects and treatments in the areas of dermatology, proctology, cardio-vascular, ophthalmology, urology, cell therapy, OB-GYN and IVD’s through both clinical studies and regulatory affairs.
Ms. Sani will advise OWCP on the transition of its innovatively-developed cannabinoid products and delivery systems to full industrial and commercial production She will supervise regulatory compliance with applicable healthcare agencies and ministries. Ms. Sani will also supervise protocol and quality compliance at manufacturing facilities of OWCP third party licensees.
Dr. Sharon Rozenblat – Advisory Board Member
Dr. Sharon Rozenblat is tasked with overseeing the completion of the pre-clinical safety studies on the Company’s treatment for psoriasis, which commenced in November 2016. Dr. Rozenblat will also steer the Company’s efforts to commercialize its cannabis-based formulations and delivery mechanisms.
Ms. Rozenblat earned her Ph.D. in biochemistry and cell biology (Magna Cum Laude) from Bar-Ilan University in Israel. Her research focused on botanical components for Melanoma (skin cancer) treatment. From 2007 to 2015, Dr. Rozenblat served as Chief Scientist at Kamedis ltd., an Israeli-based dermatological company, where she had established and managed the research and development of herbal products for the treatment of dermatological conditions.
Dr. Rozenblat was also the Scientific Director for the development of herbal extraction in a joint venture with Green Mountain Biotech (GMB), in Chengdu, China, where she worked with GMB to find agricultural resources, develop extraction methods, establish quality control methodologies, and conduct safety and efficacy studies.
Dr. Rozenblat serves as a consultant to international organizations, including as Scientific Research Director of joint development projects funded by the Korea-Israel Industrial Research and Development Foundation (KORIL), and the Israel-Singapore Foundation (SIIRD), both of which resulted in numerous products and patents.
I believe it was an interview by 1990 with Ziv